WPDPF - WPD Pharmaceuticals gives timeline update on berubicin glioblastoma trials

WPD Pharmaceuticals (WPDPF) announces that it plans to commence a phase Ib/II study of berubicin for the treatment of glioblastoma ((GBM)) in the second half of this year.CNS Pharmaceuticals (CNSP), the company that sublicenses the compound to WPD for 30 countries mainly in Europe and Asia, announces open enrollment in the U.S. for its study evaluating the efficacy and safety of berubicin in the treatment of recurrent GBM.Berubicin’s early-stage results showed promising results with 44% of the patients with GBM having a clinical response of stable disease or better based on limited clinical data, WPD said.WPD expects final approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products shortly and anticipates starting the mid-stage trial in the second half of 2021.WPD also said that it expects to commence the Phase I trial of berubicin in pediatric brain tumors in Q3/Q4 of 2021.The trials will include an interim analysis of the first 18 patients

For further details see:

WPD Pharmaceuticals gives timeline update on berubicin glioblastoma trials